Author

E. Pasquier

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Pharmacology & Toxicology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:statistical model· 5 Assay:bulk RNA-seq· 4 Research Focus:drug response / drug discovery· 4 Organism:human· 4 Approach:experimental assay· 3 Research Focus:cell type annotation· 2 Approach:deep learning· 2 Assay:scRNA-seq· 2

Frequent Co-Authors

M. Le Grand· 5 shared X. Morelli· 3 shared A. Dutour· 2 shared C. Degletagne· 2 shared I. Rochet· 2 shared J. Ariey-Bonnet· 2 shared J.-Y. Blay· 2 shared K. Carrasco· 2 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

M. Le Grand

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

BMP2 and BMP7 cooperate with H3.3K27M to promote quiescence and invasiveness in pediatric diffuse midline gliomas

P. Huchede, S. Meyer, C. Berthelot, M. Hamadou, A. Bertrand-Chapel, A. Rakotomalala, L. MANCEAU, J. Tomine, N. Lespinasse, P. Lewandowski, M. Cordier-Bussat, L. Broutier, A. Dutour, I. Rochet, J.-Y. Blay, , C. MARIE

This study shows BMP2 and BMP7 work with H3.3K27M to create a quiescent yet invasive state in pediatric gliomas.

bioRxiv · Aug 9, 2023Cancer Biology

Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms

J. Ariey-Bonnet, R. Berges, M.-P. Montero, B. Mouysset, P. Piris, K. Muller, G. Pinna, T. W. Failes, G. M. Arndt, N. Baeza-Kallee, C. Colin, O. Chinot, D. Braguer, X. Morelli, N. ANDRE, , E. Pasquier

This study identifies synergistic drug combinations for glioblastoma by screening core vulnerabilities and validating them in preclinical models.

bioRxiv · Dec 14, 2022Pharmacology & Toxicology

Fusion-negative Rhabdomyosarcoma 3D-organoids as an innovative model to predict resistance to cell death inducers

C. Savary, P. Huchede, L. Luciana, A. Tourbez, C. Deligne, C. Picard, T. Diot, C. Coquet, N. Meynard, M. Le Grand, L. Tonon, N. Gadot, C. Degletagne, S. Leon, V. Attignon, , L. Broutier

The paper develops a 3D-organoid model of fusion-negative rhabdomyosarcoma to predict resistance to cell death inducers using omics data.

bioRxiv · Sep 6, 2022 · PreprintCancer Biology

CRCM5484: A BET- BDII Selective Compound With Differential Anti-Leukemic Drug Modulation

K. Carrasco, C. Montersino, C. Derviaux, M. Saez-Ayala, L. Hoffer, A. Restouin, R. Castellano, J. Casassa, P. Roche, E. Pasquier, S. Combes, X. Morelli, Y. Collette, S. Betzi

The paper identifies CRCM5484, a BDII-selective BET inhibitor, and shows its differential modulation of anti-leukemic drug activity in combination with other compounds.

bioRxiv · Dec 13, 2021Cancer Biology

Metronomic therapy prevents emergence of drug resistance by maintaining the dynamic of intratumor heterogeneity.

M. Bondarenko, M. Le Grand, Y. Shaked, Z. Raviv, G. Chapuisat, C. Carrere, M.-P. Montero, M. Rossi, E. Pasquier, M. Carre, N. Andre

This study shows metronomic therapy better controls tumor heterogeneity than maximum-tolerated dose by leveraging drug-sensitive clones' suppressive effect on resistant ones through paracrine mechanisms.

bioRxiv · Jan 4, 2021 · PreprintCancer Biology

In silico molecular target prediction unveils mebendazole as a potent MAPK14 inhibitor

J. Ariey-Bonnet, K. Carrasco, M. Le Grand, L. Hoffer, S. Betzi, M. Feracci, P. Tsvetkov, F. Devred, Y. Collette, X. Morelli, P. Ballester, E. Pasquier

This paper identifies mebendazole as a potent MAPK14 inhibitor through in silico target prediction and experimental validation, revealing its potential for repurposing in brain tumor treatment.

bioRxiv · May 18, 2020Pharmacology & Toxicology